Statement: Throughout the duration of the primary trial, pariticpants receive increasing doses of Fulvestrant.
Primary_evidence: INTERVENTION 1:    Fulvestrant 250 mg + Tipifarnib 300 mg   Patients receive fulvestrant 250 mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity